Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

Stock Information for Achieve Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Achieve Life Sciences Inc.

Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.